Having trouble viewing this email? View in your browser.
ESCMID Logo

31 May 2016
WEEKLY NEWS

Dear colleagues,

The British Society for Antimicrobial Chemotherapy (BSAC) has draft guidelines on Multi-resistant Gram-negative Infection: Treatment open for consultation until 17 June. If you want to comment or if you need more information please consult the BSAC website.

Best regards, your ESCMID communications editors

 

CMI highlight: the threat posed by plasmid-mediated colistin resistance

Researchers from Switzerland assessed the threat posed by the emergence of plasmid-mediated colistin resistance. While the identification of MCR-1 clearly is bad news – particularly after the mechanism was also found in the U.S. – the authors conclude that it is possible to control the spread of this resistance trait to prevent its further dissemination to bacteria affecting immunocompromised patients in hospitals. The authors call for a worldwide ban of polymyxins as growth promoters in animals and a revision of the practice of using colistin-containing mixtures for selective digestive decontamination in humans. If adequate measures are rapidly taken in veterinary and human medicine it is possible to preserve the efficacy of polymyxins, which are particularly important for immunocompromised patients already infected by other multidrug-resistant bacteria, they conclude.

› Read more
 

Drive AB organizes AMR policy meeting 2 June in Amsterdam

ESCMID partner Drive-AB is organizing a conference to drive reinvestment in R&D for antibiotics and advocate their responsible use to fight antimicrobial resistance. The event supported by the Dutch EU Presidency takes place in Amsterdam 2 June. The conference is expected to stimulate a dialogue about the implementation of feasible incentive policies among international decision-makers. The speakers include policy makers, regulatory and public health experts, and economists including Dutch Health Minister Angelique Berg; Dame Sally Davies, Chief Medical Officer for England; and Hala Audi, the economist responsible for the UK Review on Antimicrobial Resistance.

› Read more
 

EORTC offers educational events on diagnostics trials or trial statistics

Our collaborative partner, the European for Research and Treatment of Cancer (EORTC) is offering a range of courses that may be of interest to specialists in the ESCMID network. Conferences and meetings include a conference on the regulatory framework governing clinical trials for in-vitro diagnostics, under courses you for example find a course on clinical trial statistics for non-statisticians and the organization also offers joint courses you may find interesting. 

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.